Literature DB >> 12410334

Inhibition of cyclooxygenase 2 by nimesulide improves cognitive outcome more than motor outcome following diffuse traumatic brain injury in rats.

Ibolja Cernak1, Christine O'Connor, Robert Vink.   

Abstract

Prostanoid synthesis is regulated by the enzyme cyclo-oxygenase (COX) that is present in at least two isoforms: COX-1, the constitutive form, and COX-2, the inducible form. Expression of COX-2 has recently been shown to be an important determinant of the cytotoxicity connected with inflammation following ischemic injury to the brain. The present study examines the temporal and spatial profiles of COX-2 expression following diffuse traumatic brain injury (TBI) in rats, and the effects of the COX-2 inhibitor nimesulide on cognitive and motor outcomes. Adult, male Sprague-Dawley rats were injured using the 2-meter impact acceleration model of diffuse TBI. At preselected time points after injury, animals were killed and the expression of COX-2 was measured in the hippocampus and parietal cortex by immunohistochemistry and Western blotting techniques. Effects of nimesulide (6 mg/kg daily over ten days) on cognitive and motor outcome was assessed in a separate group of animals using the Barnes circular maze and rotarod test, respectively. A highly significant up-regulation of COX-2 expression was found in the hippocampus as early as 3 h post-trauma and persisting for at least 12 days after TBI. In contrast, a slight but significant upregulation of COX-2 expression occurred in the cortex only at 3 days after trauma. Administration of the COX-2 inhibitor nimesulide resulted in a significant and substantial improvement in cognitive function compared to vehicle-treated controls, while motor deficits after injury was only improved at 24 h after injury. We conclude that COX-2 is involved in the development of functional deficits following diffuse TBI, particularly cognitive deficits, and that these can be improved by administration of COX-2 inhibitors.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12410334     DOI: 10.1007/s00221-002-1245-z

Source DB:  PubMed          Journal:  Exp Brain Res        ISSN: 0014-4819            Impact factor:   1.972


  31 in total

Review 1.  A review of neuroprotection pharmacology and therapies in patients with acute traumatic brain injury.

Authors:  Kevin W McConeghy; Jimmi Hatton; Lindsey Hughes; Aaron M Cook
Journal:  CNS Drugs       Date:  2012-07-01       Impact factor: 5.749

Review 2.  Therapies targeting lipid peroxidation in traumatic brain injury.

Authors:  Tamil Selvan Anthonymuthu; Elizabeth Megan Kenny; Hülya Bayır
Journal:  Brain Res       Date:  2016-02-10       Impact factor: 3.252

Review 3.  Bridge between neuroimmunity and traumatic brain injury.

Authors:  Matthew L Kelso; Howard E Gendelman
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

Review 4.  The distinct roles of cyclooxygenase-1 and -2 in neuroinflammation: implications for translational research.

Authors:  Sang-Ho Choi; Saba Aid; Francesca Bosetti
Journal:  Trends Pharmacol Sci       Date:  2009-03-09       Impact factor: 14.819

5.  Pyridoxine administration improves behavioral and anatomical outcome after unilateral contusion injury in the rat.

Authors:  Nicholas J Kuypers; Michael R Hoane
Journal:  J Neurotrauma       Date:  2010-07       Impact factor: 5.269

6.  Animal Models of Posttraumatic Seizures and Epilepsy.

Authors:  Alexander V Glushakov; Olena Y Glushakova; Sylvain Doré; Paul R Carney; Ronald L Hayes
Journal:  Methods Mol Biol       Date:  2016

7.  Cyclooxygenase-2-specific inhibitor improves functional outcomes, provides neuroprotection, and reduces inflammation in a rat model of traumatic brain injury.

Authors:  Jonas J Gopez; Hongfei Yue; Ram Vasudevan; Amir S Malik; Lester N Fogelsanger; Shawn Lewis; David Panikashvili; Esther Shohami; Susan A Jansen; Raj K Narayan; Kenneth I Strauss
Journal:  Neurosurgery       Date:  2005-03       Impact factor: 4.654

Review 8.  Antiinflammatory and neuroprotective actions of COX2 inhibitors in the injured brain.

Authors:  Kenneth I Strauss
Journal:  Brain Behav Immun       Date:  2007-11-08       Impact factor: 7.217

Review 9.  Using anesthetics and analgesics in experimental traumatic brain injury.

Authors:  Rachel K Rowe; Jordan L Harrison; Theresa C Thomas; James R Pauly; P David Adelson; Jonathan Lifshitz
Journal:  Lab Anim (NY)       Date:  2013-08       Impact factor: 12.625

10.  Effects of genetic deficiency of cyclooxygenase-1 or cyclooxygenase-2 on functional and histological outcomes following traumatic brain injury in mice.

Authors:  Matthew L Kelso; Stephen W Scheff; James R Pauly; Charles D Loftin
Journal:  BMC Neurosci       Date:  2009-08-31       Impact factor: 3.288

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.